HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

BMC Cancer

Table 1 Patient characteristics

Variable	n	%	N available
Sex			229
Female	228	99.6
Male	1	0.4
Age, years [range]	51 [24–83]		229
Menopause			228
Yes	118	51.8
No	110	48.2
Histology			237^a
NST	214	90.3
Lobular	17	7.2
Other	6	2.5
HR			237^a
positive	152	64.1
negative	85	35.9
ER			237^a
< 10%	88	37.1
≥ 10%	149	62.9
PR			237^a
< 10%	134	56.5
≥ 10%	103	43.5
HER2			237^a
1 +	160	67.5
2 +	77	32.5
Baseline NLR			226
> 1.96	104	46.0
< 1.96	122	53.9
Stage			237^a
IA	8	3.4
IB	80	33.8
IIA	84	35.4
IIB	29	12.2
IIIA	33	13.9
IIIB	3	1.3
Chemotherapy regimen			229
12 paclitaxel	3	1.3
3 (F)EC—3 docetaxel	141	61.6
3 (F)EC—9–12 paclitaxel	48	21.0
4 (F)EC—4 docetaxel	5	2.2
4 (F)EC—9–12 paclitaxel	15	6.6
4 carboplatinum-paclitaxel—4EC	1	0.4
4 carboplatinum-paclitaxel—4AC	1	0.4
4–6 docetaxel—cyclophosphamide	2	0.9
6 docetaxel—epirubicine	11	4.8
6 docetaxel	1	0.4
6 carboplatinum—paclitaxel	1	0.4
Surgery			229
Partial mastectomy + SLN biopsy	43	18.8
Partial mastectomy + ALND	72	31.4
Total mastectomy + SLN biopsy	91	39.7
Total mastectomy + ALND	17	7.4
Total mastectomy without ALND	6	2.6
Response to neoadjuvant chemotherapy
Sataloff score			213
Complete response = TANA / TANB	37	17.4
No pCR	176	82.6
RCB score			106
Complete response = 0	15	14.2
No pCR	91	85.8

With NST No Special Type, ER Estrogen receptor, PR Progesterone receptor, HER2 Human epidermal growth factor receptor 2, NLR Neutrophil-to-Lymphocyte Ratio, (F)EC (fluorouracil) – epirubicin – cyclophosphamide, AC Adriamycin – cyclophosphamide, RCB Residual breast Cancer Burden, ALND Axillary lymph node dissection, pCR Pathological complete response, SLN Sentinel lymph node
^a Corresponding to the number of tumors

ISSN: 1471-2407